ABCELLERA BIOLOGICS (8QQ) — Capital Reinvestment Ratio

Latest as of June 2026: 0.08x

ABCELLERA BIOLOGICS (8QQ) has a Capital Reinvestment Ratio of 0.08x as of June 2026, meaning it reinvests 0% of its operating cash flow (€25.92 Million) in capital expenditures (€2.13 Million). Check tangible equity quality of ABCELLERA BIOLOGICS to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.08x
Capex / Operating Cash Flow

Operating Cash Flow

€25.92 Million
EUR

Capital Expenditures

€2.13 Million
EUR

Data as of

Jun 2026
Most recent filing

ABCELLERA BIOLOGICS Capital Reinvestment Ratio (2021–2022)

This chart tracks ABCELLERA BIOLOGICS's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see ABCELLERA BIOLOGICS (8QQ) cash flow conversion.

Annual Capital Reinvestment Ratio for ABCELLERA BIOLOGICS (2021–2022)

Year-by-year Capital Reinvestment Ratio for ABCELLERA BIOLOGICS from 2021 to 2022. See ABCELLERA BIOLOGICS free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2022 0.26x €277.36 Million €72.66 Million ▲ +9.6%
2021 0.24x €244.58 Million €58.45 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow